• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CG1
Click for more information
1.45% 7.0¢

CARBONXT GROUP LIMITED - News & Media

Market Cap $25.62M  ! watchlist Created with Sketch. Add to my watchlist
Chemicals Basic Materials Basic Materials Chemicals Basic Materials Basic Materials Basic Materials

Carbonxt Group Limited is a cleantech company. The Company is engaged in the development... Carbonxt Group Limited is a cleantech company. The Company is engaged in the development and sale of specialized Activated Carbon (AC) products, including Powdered Activated Carbon (PAC) and AC pellets for the removal of pollutants and toxins in industrial processes. Its products are used in industrial air purification, wastewater treatment and other liquid and gas phase markets, primarily for the capture of mercury and sulfur in order to reduce harmful emissions into the atmosphere. Its products include MATS-PAC, MATS-PACK S, CXT-WETJECT, CXT-NAQ-ACP, CEM-PAC, CEM-PAC-S, MACT-PAC, CXT-BB500, CXT-BB600, CXT-BB800, CXT-BB+, CXT-ACP60V, CXT-ACP50V, CXT-ACP45V, CXT-AQP50 and HYDRESTOR. The Company’s products application includes nutrient recovery technology, coal-fired power plants, cement plants, waste to energy: industrial boilers and incinerators, potable water, and volatile organic compounds (VOC) and contaminant removal.More

No News & Media currently available.

(20min delay)
Last
7.0¢ 		Change
0.001(1.45%) 		Mkt cap ! $25.62M
Open High Low Value Volume
6.9¢ 7.0¢ 6.9¢ $788 11.27K

Buyers (Bids)

No. Vol. Price($)
1 13674 7.0¢
 

Sellers (Offers)

Price($) Vol. No.
7.1¢ 200219 2
View Market Depth
Last trade - 10.58am 02/10/2024 (20 minute delay) ?
Last
7.0¢ 		  Change
0.001 ( 1.45 %)
Open High Low Volume
7.0¢ 7.0¢ 7.0¢ 46398
Last updated 10.58am 02/10/2024 ?
CG1 (ASX) Chart

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Maximus jumps 7% as it unveils latest gold drill hits at Eagles Nest; grades up to 15g/t Maximus Resources (ASX:MXR) has unveiled its latest drilling assay results at Eagles Nest, hitting gold downhole multiple assets.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
PainChek close to finding out if FDA approves its flagship app for use in dementia care PainChek (ASX:PCK) has updated the market on the progress of its De Novo submission to the US FDA for its flagship app in aged care settings.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.